39741-46-3

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Bromo-5-(chloromethyl)pyridine hydrochloride is utilized as a key intermediate in the production of pharmaceuticals. Its unique structure allows it to participate in a range of chemical reactions that are essential for the synthesis of various medicinal compounds.
Used in Agrochemical Production:
3-BROMO-5-(CHLOROMETHYL)PYRIDINE HYDROCHLORIDE also serves as an intermediate in the synthesis of agrochemicals, contributing to the development of products designed to enhance crop protection and improve agricultural yields.
Used in Dye Manufacturing:
3-Bromo-5-(chloromethyl)pyridine hydrochloride is employed in the manufacture of dyes due to its ability to form colored compounds, which are valuable in various industries that rely on colorants for their products.
Used in Organic Compound Synthesis:
Its versatility in chemical reactions makes 3-Bromo-5-(chloromethyl)pyridine hydrochloride a useful building block in the synthesis of a wide array of organic compounds, expanding its applications across different chemical and industrial sectors.

InChI:InChI=1/C6H5BrClN.ClH/c7-6-1-5(2-8)3-9-4-6;/h1,3-4H,2H2;1H

Upstream product

• 37669-64-0 (5-bromopyridin-3-yl)methanol 
• 29681-44-5 5-bromo-3-pyridine carboxylic acid methyl ester 
• 113118-81-3 5-bromopyridine-3-carbaldehyde 
• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 
• 22620-36-6 3-bromo-5-(hydroxymethyl)pyridine hydrochloride 

Downstream Products

• 143770-59-6 5-bromo-3-(3-methylanilino)methylpyridine 
• 943722-24-5 3-bromo-5-(tert-butoxycarbonyl)aminomethylpyridine 
• 1332502-86-9 2-[(5-bromopyridin-3-yl)methyl]-5-(4-chlorophenyl)-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 1332502-85-8 2-[(5-bromopyridin-3-yl)methyl]-5-(4-chlorophenyl)-4-(3,3,3-trifluoro-2-hydroxypropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 847375-33-1 (5-bromo-pyridin-3-yl)-acetic acid ethyl ester 
• 39891-08-2 (5-bromo-pyridin-3-yl)-acetonitrile 
• 1255870-19-9 2-chloro-4-[5-(1,1-dioxo-isothiazoiidin-2-ylmethyl)-pyridin-3-yl]-benzonitrile 
• 1246034-49-0 [(5-bromo-3-pyridinyl)methyl][2-(methyloxy)ethyl]amine 
• 364793-91-9 4-((5-bromopyridin-3-yl)methyl)morpholine 
• 166094-31-1 3-(N,N-dimethylthiocarbamoyl)-5-(2-tert-butyldiphenylsilyloxyethoxymethyl)pyridine 
• 166094-28-6 3-(N,N-dimethylcarbamoyl)-5-(2-tert-butyldiphenylsilyloxyethoxymethyl)pyridine 
• 166094-30-0 3-(N-methylthiocarbamoyl)-5-(2-tert-butyldiphenylsilyloxyethoxymethyl)pyridine 
• 166094-22-0 5-(2-tert-butyldiphenylsilyloxyethoxymethyl)-3-methoxycarbonylpyridine 
• 166094-27-5 3-(N-methylcarbamoyl)-5-(2-tert-butyldiphenylsilyloxyethoxymethyl)pyridine 

Relevant academic research and scientific papers

METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.

INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

lndazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole-3- carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

ALDOSTERONE SYNTHASE INHIBITORS

This invention relates to tricyclic triazole analogues of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.

SUBSTITUTED PYRAZOLE DERIVATIVES

The present invention provides a novel pyrazole derivative and an androgen receptor antagonist containing the derivative. The present invention provides a compound represented by the formula (I′) wherein R1 is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom, or a group via a sulfur atom; R2 is a phenyl group having cyano (the phenyl group may further have substituent(s) other than cyano); R3 is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom, or a group via a sulfur atom; R4 is a cyclic group optionally having substituent(s); and X is methylene optionally having substituent(s), or CO, or a salt thereof.

Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use

Amide compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

Synthesis and biological evaluation of some acyclic pyridine C- nucleosides. Part one

The reaction between 3-bromo-5-chloromethylpyridine hydrochloride (4) with the mono sodium salt of ethylene glycol was investigated. 3-Bromo-5-(2- hydroxyethoxymethyl)-pyridine (5) was synthesized and converted to the 3- carboxy analogue using butyllithiu